BACKGROUND: Little is known about the serotonin-1A receptor (5-HT1A) in bipolar depression despite altered 5-HT1A binding in major depressive disorder. Utilizing positron emission tomography (PET) and the radioligand N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide ([Carbonyl-C-11]WAY-100635), 5-HT1A binding was compared between depressed bipolar disorder (BD) and controls. METHODS: Brain 5-HT1A binding potential (BP(F) = B(max)/K(D), where B(max) = total available receptors, and 1/K(D) = ligand affinity) was measured in 32 currently depressed, medication-free BD subjects and 47 controls. Participants were genotyped for the 5-HT1A promoter polymorphism C(-1019)G. RESULTS: The bipolar depressed group demonstrated higher 5-HT1A BP(F) across all regions of interest (ROIs; p = .022). Post hoc analyses indicated that male BD patients had higher 5-HT1A BP(F) than male controls (p = .025), with higher 5-HT1A BP(F) found in every region (by 102% in raphe nuclei and 29% to 50% in the forebrain ROIs); whereas, female subgroups did not differ in 5-HT1A BP(F) (p = .32). Serotonin-1A BP(F) did not correlate with depression severity. The GG genotype was overrepresented at trend level in the BD group (p = .057). Number of G-allele copies was associated with higher 5-HT1A BP(F) in raphe (p = .0050), amygdala (p = .022), and hippocampus (p = .041). CONCLUSIONS: Higher 5-HT1A BP(F) in bipolar depressed males suggests higher raphe autoreceptor binding, potentially causing less serotonin release and compensatory upregulation of forebrain postsynaptic 5-HT1A receptors. The raphe effect may be partly genetic. No difference in 5-HT1A BP(F) between BD and control females may reflect greater effect of prior antidepressant exposure in BD females.
BACKGROUND: Little is known about the serotonin-1A receptor (5-HT1A) in bipolar depression despite altered 5-HT1A binding in major depressive disorder. Utilizing positron emission tomography (PET) and the radioligand N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide ([Carbonyl-C-11]WAY-100635), 5-HT1A binding was compared between depressed bipolar disorder (BD) and controls. METHODS:Brain 5-HT1A binding potential (BP(F) = B(max)/K(D), where B(max) = total available receptors, and 1/K(D) = ligand affinity) was measured in 32 currently depressed, medication-free BD subjects and 47 controls. Participants were genotyped for the 5-HT1A promoter polymorphism C(-1019)G. RESULTS: The bipolar depressed group demonstrated higher 5-HT1A BP(F) across all regions of interest (ROIs; p = .022). Post hoc analyses indicated that male BD patients had higher 5-HT1A BP(F) than male controls (p = .025), with higher 5-HT1A BP(F) found in every region (by 102% in raphe nuclei and 29% to 50% in the forebrain ROIs); whereas, female subgroups did not differ in 5-HT1A BP(F) (p = .32). Serotonin-1A BP(F) did not correlate with depression severity. The GG genotype was overrepresented at trend level in the BD group (p = .057). Number of G-allele copies was associated with higher 5-HT1A BP(F) in raphe (p = .0050), amygdala (p = .022), and hippocampus (p = .041). CONCLUSIONS: Higher 5-HT1A BP(F) in bipolar depressed males suggests higher raphe autoreceptor binding, potentially causing less serotonin release and compensatory upregulation of forebrain postsynaptic 5-HT1A receptors. The raphe effect may be partly genetic. No difference in 5-HT1A BP(F) between BD and control females may reflect greater effect of prior antidepressant exposure in BD females.
Authors: R V Parsey; M Slifstein; D R Hwang; A Abi-Dargham; N Simpson; O Mawlawi; N N Guo; R Van Heertum; J J Mann; M Laruelle Journal: J Cereb Blood Flow Metab Date: 2000-07 Impact factor: 6.200
Authors: W C Drevets; E Frank; J C Price; D J Kupfer; D Holt; P J Greer; Y Huang; C Gautier; C Mathis Journal: Biol Psychiatry Date: 1999-11-15 Impact factor: 13.382
Authors: Laurent Naudon; Malika El Yacoubi; Jean-Marie Vaugeois; Isabelle Leroux-Nicollet; Jean Costentin Journal: Brain Res Date: 2002-05-17 Impact factor: 3.252
Authors: D K Raap; L DonCarlos; F Garcia; N A Muma; W A Wolf; G Battaglia; L D Van de Kar Journal: Neuropharmacology Date: 2000-07-24 Impact factor: 5.250
Authors: Lewis L Judd; Hagop S Akiskal; Pamela J Schettler; Jean Endicott; Jack Maser; David A Solomon; Andrew C Leon; John A Rice; Martin B Keller Journal: Arch Gen Psychiatry Date: 2002-06
Authors: Eugenii A Rabiner; Martin R Wilkins; Federico Turkheimer; Roger N Gunn; Joanna Udo de Haes; Michiel de Vries; Paul M Grasby Journal: J Pharmacol Exp Ther Date: 2002-06 Impact factor: 4.030
Authors: Andreas Hahn; Wolfgang Wadsak; Christian Windischberger; Pia Baldinger; Anna S Höflich; Jan Losak; Lukas Nics; Cécile Philippe; Georg S Kranz; Christoph Kraus; Markus Mitterhauser; Georgios Karanikas; Siegfried Kasper; Rupert Lanzenberger Journal: Proc Natl Acad Sci U S A Date: 2012-01-30 Impact factor: 11.205
Authors: Matthew S Milak; Spiro Pantazatos; Rain Rashid; Francesca Zanderigo; Christine DeLorenzo; Natalie Hesselgrave; R Todd Ogden; Maria A Oquendo; Stephanie T Mulhern; Jeffrey M Miller; Ainsley K Burke; Ramin V Parsey; J John Mann Journal: Psychiatry Res Neuroimaging Date: 2018-04-13 Impact factor: 2.376
Authors: Rajapillai L I Pillai; Elizabeth A Bartlett; Mala R Ananth; Chencan Zhu; Jie Yang; Greg Hajcak; Ramin V Parsey; Christine DeLorenzo Journal: Neuroimage Date: 2020-03-10 Impact factor: 6.556
Authors: Allison C Nugent; Earle E Bain; Paul J Carlson; Alexander Neumeister; Omer Bonne; Richard E Carson; William Eckelman; Peter Herscovitch; Carlos A Zarate; Dennis S Charney; Wayne C Drevets Journal: Eur Neuropsychopharmacol Date: 2013-02-20 Impact factor: 4.600
Authors: Jeffrey M Miller; Natalie Hesselgrave; R Todd Ogden; Gregory M Sullivan; Maria A Oquendo; J John Mann; Ramin V Parsey Journal: Biol Psychiatry Date: 2013-03-01 Impact factor: 13.382
Authors: M Embree; V Michopoulos; J R Votaw; R J Voll; J Mun; J S Stehouwer; M M Goodman; M E Wilson; M M Sánchez Journal: Neuroscience Date: 2012-10-16 Impact factor: 3.590